Loading…

Chronic Kidney Disease Stage Progression in Liver Transplant Recipients

There is little information on chronic kidney disease (CKD) stage progression rates and outcomes in liver transplant recipients. Identifying modifiable risk factors may help prevent CKD progression in liver transplant recipients. We performed a retrospective review of 1151 adult, deceased-donor, sin...

Full description

Saved in:
Bibliographic Details
Published in:Clinical journal of the American Society of Nephrology 2011-08, Vol.6 (8), p.1851-1857
Main Authors: Lamattina, John C, Foley, David P, Mezrich, Joshua D, Fernandez, Luis A, Vidyasagar, Vijay, D'Alessandro, Anthony M, Musat, Alexandru I, Samaniego-Picota, Milagros D, Pascual, Julio, Alejandro, Munoz D R, Leverson, Glen E, Pirsch, John D, Djamali, Arjang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c481t-fa6bab03d1262d61a02c86d587dd71b1bc62a2550acff3e688fecb93c0e158173
cites cdi_FETCH-LOGICAL-c481t-fa6bab03d1262d61a02c86d587dd71b1bc62a2550acff3e688fecb93c0e158173
container_end_page 1857
container_issue 8
container_start_page 1851
container_title Clinical journal of the American Society of Nephrology
container_volume 6
creator Lamattina, John C
Foley, David P
Mezrich, Joshua D
Fernandez, Luis A
Vidyasagar, Vijay
D'Alessandro, Anthony M
Musat, Alexandru I
Samaniego-Picota, Milagros D
Pascual, Julio
Alejandro, Munoz D R
Leverson, Glen E
Pirsch, John D
Djamali, Arjang
description There is little information on chronic kidney disease (CKD) stage progression rates and outcomes in liver transplant recipients. Identifying modifiable risk factors may help prevent CKD progression in liver transplant recipients. We performed a retrospective review of 1151 adult, deceased-donor, single-organ primary liver transplants between July 1984 and December 2007 and analyzed kidney outcomes and risk factors for CKD stage progression. Seven hundred twenty-nine patients had an available estimated GFR at 1 year posttransplant to establish a baseline stage. The primary end point was the CKD progression from one stage to a higher stage (lower GFR). Kaplan-Meier estimates of patient survival were 91%, 74%, and 64% at 5, 10, and 15 years, respectively. Estimates of liver allograft survival were 89%, 71%, and 60% at the same time points. At 1 year, 7%, 34%, 56%, 3%, and 1% of patients were in CKD stages 1, 2, 3, 4, and 5. The incidence of stage progression was 28%, 40%, and 53% at 3, 5, and 10 years. The incidence of ESRD was 2.6%, 7.5%, and 18% at 5, 10, and 20 years. Multivariable Cox regression analyses demonstrated that CKD stage at 1 year, pretransplant diabetes and urinary tract infections/hypercholesterolemia in the first year proved to be independent risk factors for stage progression (hazard ratio 1.9, 0.28, 1.39, and 1.46, respectively, P < 0.05). Future studies will determine whether treatment of risk factors in the first posttransplant year prevent CKD progression in liver transplant recipients.
doi_str_mv 10.2215/CJN.00650111
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3359532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>882088303</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-fa6bab03d1262d61a02c86d587dd71b1bc62a2550acff3e688fecb93c0e158173</originalsourceid><addsrcrecordid>eNpVkE1PAjEQhhujEUVvns3evAh22u1SLiYGFT-IGsXEW9PtzkLJ0sV2wfDvXcOHeuokffK-Mw8hJ0DbjIG46D08tSlNBAWAHXIAQohWl4qP3e0cQ4MchjChNI45E_ukwaAjY8n4Aen3xr501kSPNnO4jK5tQB0weqv0CKMXX448hmBLF1kXDewCfTT02oVZoV0VvaKxM4uuCkdkL9dFwOP12yTvtzfD3l1r8Ny_710NWiaWULVynaQ6pTwDlrAsAU2ZkUkmZCfLOpBCahKmmRBUmzznmEiZo0m73FAEIaHDm-RylTubp1PMTN3tdaFm3k61X6pSW_X_x9mxGpULxbnoCs7qgLN1gC8_5xgqNbXBYFHfg-U8KCkZlZJTXpPnK9L4MgSP-bYFqPpRr2r1aqO-xk__braFN65_m8d2NP6yHlWY6qKocabMRAeXKKlACuDfe9yNvg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>882088303</pqid></control><display><type>article</type><title>Chronic Kidney Disease Stage Progression in Liver Transplant Recipients</title><source>American Society of Nephrology</source><source>PubMed Central</source><creator>Lamattina, John C ; Foley, David P ; Mezrich, Joshua D ; Fernandez, Luis A ; Vidyasagar, Vijay ; D'Alessandro, Anthony M ; Musat, Alexandru I ; Samaniego-Picota, Milagros D ; Pascual, Julio ; Alejandro, Munoz D R ; Leverson, Glen E ; Pirsch, John D ; Djamali, Arjang</creator><creatorcontrib>Lamattina, John C ; Foley, David P ; Mezrich, Joshua D ; Fernandez, Luis A ; Vidyasagar, Vijay ; D'Alessandro, Anthony M ; Musat, Alexandru I ; Samaniego-Picota, Milagros D ; Pascual, Julio ; Alejandro, Munoz D R ; Leverson, Glen E ; Pirsch, John D ; Djamali, Arjang</creatorcontrib><description>There is little information on chronic kidney disease (CKD) stage progression rates and outcomes in liver transplant recipients. Identifying modifiable risk factors may help prevent CKD progression in liver transplant recipients. We performed a retrospective review of 1151 adult, deceased-donor, single-organ primary liver transplants between July 1984 and December 2007 and analyzed kidney outcomes and risk factors for CKD stage progression. Seven hundred twenty-nine patients had an available estimated GFR at 1 year posttransplant to establish a baseline stage. The primary end point was the CKD progression from one stage to a higher stage (lower GFR). Kaplan-Meier estimates of patient survival were 91%, 74%, and 64% at 5, 10, and 15 years, respectively. Estimates of liver allograft survival were 89%, 71%, and 60% at the same time points. At 1 year, 7%, 34%, 56%, 3%, and 1% of patients were in CKD stages 1, 2, 3, 4, and 5. The incidence of stage progression was 28%, 40%, and 53% at 3, 5, and 10 years. The incidence of ESRD was 2.6%, 7.5%, and 18% at 5, 10, and 20 years. Multivariable Cox regression analyses demonstrated that CKD stage at 1 year, pretransplant diabetes and urinary tract infections/hypercholesterolemia in the first year proved to be independent risk factors for stage progression (hazard ratio 1.9, 0.28, 1.39, and 1.46, respectively, P &lt; 0.05). Future studies will determine whether treatment of risk factors in the first posttransplant year prevent CKD progression in liver transplant recipients.</description><identifier>ISSN: 1555-9041</identifier><identifier>EISSN: 1555-905X</identifier><identifier>DOI: 10.2215/CJN.00650111</identifier><identifier>PMID: 21784823</identifier><language>eng</language><publisher>United States: American Society of Nephrology</publisher><subject>Adult ; Chronic Disease ; Disease Progression ; Female ; Glomerular Filtration Rate ; Graft Survival ; Humans ; Incidence ; Kaplan-Meier Estimate ; Kidney - physiopathology ; Kidney Diseases - epidemiology ; Kidney Diseases - mortality ; Kidney Diseases - physiopathology ; Kidney Failure, Chronic - epidemiology ; Kidney Failure, Chronic - mortality ; Kidney Failure, Chronic - physiopathology ; Liver Transplantation - adverse effects ; Liver Transplantation - mortality ; Male ; Middle Aged ; Original ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Survival Rate ; Time Factors ; Wisconsin - epidemiology</subject><ispartof>Clinical journal of the American Society of Nephrology, 2011-08, Vol.6 (8), p.1851-1857</ispartof><rights>Copyright © 2011 by the American Society of Nephrology 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-fa6bab03d1262d61a02c86d587dd71b1bc62a2550acff3e688fecb93c0e158173</citedby><cites>FETCH-LOGICAL-c481t-fa6bab03d1262d61a02c86d587dd71b1bc62a2550acff3e688fecb93c0e158173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359532/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359532/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4011,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21784823$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamattina, John C</creatorcontrib><creatorcontrib>Foley, David P</creatorcontrib><creatorcontrib>Mezrich, Joshua D</creatorcontrib><creatorcontrib>Fernandez, Luis A</creatorcontrib><creatorcontrib>Vidyasagar, Vijay</creatorcontrib><creatorcontrib>D'Alessandro, Anthony M</creatorcontrib><creatorcontrib>Musat, Alexandru I</creatorcontrib><creatorcontrib>Samaniego-Picota, Milagros D</creatorcontrib><creatorcontrib>Pascual, Julio</creatorcontrib><creatorcontrib>Alejandro, Munoz D R</creatorcontrib><creatorcontrib>Leverson, Glen E</creatorcontrib><creatorcontrib>Pirsch, John D</creatorcontrib><creatorcontrib>Djamali, Arjang</creatorcontrib><title>Chronic Kidney Disease Stage Progression in Liver Transplant Recipients</title><title>Clinical journal of the American Society of Nephrology</title><addtitle>Clin J Am Soc Nephrol</addtitle><description>There is little information on chronic kidney disease (CKD) stage progression rates and outcomes in liver transplant recipients. Identifying modifiable risk factors may help prevent CKD progression in liver transplant recipients. We performed a retrospective review of 1151 adult, deceased-donor, single-organ primary liver transplants between July 1984 and December 2007 and analyzed kidney outcomes and risk factors for CKD stage progression. Seven hundred twenty-nine patients had an available estimated GFR at 1 year posttransplant to establish a baseline stage. The primary end point was the CKD progression from one stage to a higher stage (lower GFR). Kaplan-Meier estimates of patient survival were 91%, 74%, and 64% at 5, 10, and 15 years, respectively. Estimates of liver allograft survival were 89%, 71%, and 60% at the same time points. At 1 year, 7%, 34%, 56%, 3%, and 1% of patients were in CKD stages 1, 2, 3, 4, and 5. The incidence of stage progression was 28%, 40%, and 53% at 3, 5, and 10 years. The incidence of ESRD was 2.6%, 7.5%, and 18% at 5, 10, and 20 years. Multivariable Cox regression analyses demonstrated that CKD stage at 1 year, pretransplant diabetes and urinary tract infections/hypercholesterolemia in the first year proved to be independent risk factors for stage progression (hazard ratio 1.9, 0.28, 1.39, and 1.46, respectively, P &lt; 0.05). Future studies will determine whether treatment of risk factors in the first posttransplant year prevent CKD progression in liver transplant recipients.</description><subject>Adult</subject><subject>Chronic Disease</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glomerular Filtration Rate</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Kidney - physiopathology</subject><subject>Kidney Diseases - epidemiology</subject><subject>Kidney Diseases - mortality</subject><subject>Kidney Diseases - physiopathology</subject><subject>Kidney Failure, Chronic - epidemiology</subject><subject>Kidney Failure, Chronic - mortality</subject><subject>Kidney Failure, Chronic - physiopathology</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver Transplantation - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Wisconsin - epidemiology</subject><issn>1555-9041</issn><issn>1555-905X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNpVkE1PAjEQhhujEUVvns3evAh22u1SLiYGFT-IGsXEW9PtzkLJ0sV2wfDvXcOHeuokffK-Mw8hJ0DbjIG46D08tSlNBAWAHXIAQohWl4qP3e0cQ4MchjChNI45E_ukwaAjY8n4Aen3xr501kSPNnO4jK5tQB0weqv0CKMXX448hmBLF1kXDewCfTT02oVZoV0VvaKxM4uuCkdkL9dFwOP12yTvtzfD3l1r8Ny_710NWiaWULVynaQ6pTwDlrAsAU2ZkUkmZCfLOpBCahKmmRBUmzznmEiZo0m73FAEIaHDm-RylTubp1PMTN3tdaFm3k61X6pSW_X_x9mxGpULxbnoCs7qgLN1gC8_5xgqNbXBYFHfg-U8KCkZlZJTXpPnK9L4MgSP-bYFqPpRr2r1aqO-xk__braFN65_m8d2NP6yHlWY6qKocabMRAeXKKlACuDfe9yNvg</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>Lamattina, John C</creator><creator>Foley, David P</creator><creator>Mezrich, Joshua D</creator><creator>Fernandez, Luis A</creator><creator>Vidyasagar, Vijay</creator><creator>D'Alessandro, Anthony M</creator><creator>Musat, Alexandru I</creator><creator>Samaniego-Picota, Milagros D</creator><creator>Pascual, Julio</creator><creator>Alejandro, Munoz D R</creator><creator>Leverson, Glen E</creator><creator>Pirsch, John D</creator><creator>Djamali, Arjang</creator><general>American Society of Nephrology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110801</creationdate><title>Chronic Kidney Disease Stage Progression in Liver Transplant Recipients</title><author>Lamattina, John C ; Foley, David P ; Mezrich, Joshua D ; Fernandez, Luis A ; Vidyasagar, Vijay ; D'Alessandro, Anthony M ; Musat, Alexandru I ; Samaniego-Picota, Milagros D ; Pascual, Julio ; Alejandro, Munoz D R ; Leverson, Glen E ; Pirsch, John D ; Djamali, Arjang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-fa6bab03d1262d61a02c86d587dd71b1bc62a2550acff3e688fecb93c0e158173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Chronic Disease</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glomerular Filtration Rate</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Kidney - physiopathology</topic><topic>Kidney Diseases - epidemiology</topic><topic>Kidney Diseases - mortality</topic><topic>Kidney Diseases - physiopathology</topic><topic>Kidney Failure, Chronic - epidemiology</topic><topic>Kidney Failure, Chronic - mortality</topic><topic>Kidney Failure, Chronic - physiopathology</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver Transplantation - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Wisconsin - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamattina, John C</creatorcontrib><creatorcontrib>Foley, David P</creatorcontrib><creatorcontrib>Mezrich, Joshua D</creatorcontrib><creatorcontrib>Fernandez, Luis A</creatorcontrib><creatorcontrib>Vidyasagar, Vijay</creatorcontrib><creatorcontrib>D'Alessandro, Anthony M</creatorcontrib><creatorcontrib>Musat, Alexandru I</creatorcontrib><creatorcontrib>Samaniego-Picota, Milagros D</creatorcontrib><creatorcontrib>Pascual, Julio</creatorcontrib><creatorcontrib>Alejandro, Munoz D R</creatorcontrib><creatorcontrib>Leverson, Glen E</creatorcontrib><creatorcontrib>Pirsch, John D</creatorcontrib><creatorcontrib>Djamali, Arjang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical journal of the American Society of Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamattina, John C</au><au>Foley, David P</au><au>Mezrich, Joshua D</au><au>Fernandez, Luis A</au><au>Vidyasagar, Vijay</au><au>D'Alessandro, Anthony M</au><au>Musat, Alexandru I</au><au>Samaniego-Picota, Milagros D</au><au>Pascual, Julio</au><au>Alejandro, Munoz D R</au><au>Leverson, Glen E</au><au>Pirsch, John D</au><au>Djamali, Arjang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic Kidney Disease Stage Progression in Liver Transplant Recipients</atitle><jtitle>Clinical journal of the American Society of Nephrology</jtitle><addtitle>Clin J Am Soc Nephrol</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>6</volume><issue>8</issue><spage>1851</spage><epage>1857</epage><pages>1851-1857</pages><issn>1555-9041</issn><eissn>1555-905X</eissn><abstract>There is little information on chronic kidney disease (CKD) stage progression rates and outcomes in liver transplant recipients. Identifying modifiable risk factors may help prevent CKD progression in liver transplant recipients. We performed a retrospective review of 1151 adult, deceased-donor, single-organ primary liver transplants between July 1984 and December 2007 and analyzed kidney outcomes and risk factors for CKD stage progression. Seven hundred twenty-nine patients had an available estimated GFR at 1 year posttransplant to establish a baseline stage. The primary end point was the CKD progression from one stage to a higher stage (lower GFR). Kaplan-Meier estimates of patient survival were 91%, 74%, and 64% at 5, 10, and 15 years, respectively. Estimates of liver allograft survival were 89%, 71%, and 60% at the same time points. At 1 year, 7%, 34%, 56%, 3%, and 1% of patients were in CKD stages 1, 2, 3, 4, and 5. The incidence of stage progression was 28%, 40%, and 53% at 3, 5, and 10 years. The incidence of ESRD was 2.6%, 7.5%, and 18% at 5, 10, and 20 years. Multivariable Cox regression analyses demonstrated that CKD stage at 1 year, pretransplant diabetes and urinary tract infections/hypercholesterolemia in the first year proved to be independent risk factors for stage progression (hazard ratio 1.9, 0.28, 1.39, and 1.46, respectively, P &lt; 0.05). Future studies will determine whether treatment of risk factors in the first posttransplant year prevent CKD progression in liver transplant recipients.</abstract><cop>United States</cop><pub>American Society of Nephrology</pub><pmid>21784823</pmid><doi>10.2215/CJN.00650111</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1555-9041
ispartof Clinical journal of the American Society of Nephrology, 2011-08, Vol.6 (8), p.1851-1857
issn 1555-9041
1555-905X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3359532
source American Society of Nephrology; PubMed Central
subjects Adult
Chronic Disease
Disease Progression
Female
Glomerular Filtration Rate
Graft Survival
Humans
Incidence
Kaplan-Meier Estimate
Kidney - physiopathology
Kidney Diseases - epidemiology
Kidney Diseases - mortality
Kidney Diseases - physiopathology
Kidney Failure, Chronic - epidemiology
Kidney Failure, Chronic - mortality
Kidney Failure, Chronic - physiopathology
Liver Transplantation - adverse effects
Liver Transplantation - mortality
Male
Middle Aged
Original
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
Survival Rate
Time Factors
Wisconsin - epidemiology
title Chronic Kidney Disease Stage Progression in Liver Transplant Recipients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T01%3A58%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20Kidney%20Disease%20Stage%20Progression%20in%20Liver%20Transplant%20Recipients&rft.jtitle=Clinical%20journal%20of%20the%20American%20Society%20of%20Nephrology&rft.au=Lamattina,%20John%20C&rft.date=2011-08-01&rft.volume=6&rft.issue=8&rft.spage=1851&rft.epage=1857&rft.pages=1851-1857&rft.issn=1555-9041&rft.eissn=1555-905X&rft_id=info:doi/10.2215/CJN.00650111&rft_dat=%3Cproquest_pubme%3E882088303%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c481t-fa6bab03d1262d61a02c86d587dd71b1bc62a2550acff3e688fecb93c0e158173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=882088303&rft_id=info:pmid/21784823&rfr_iscdi=true